EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, CTI BioPharma's enterprise value is $1,188.68 Mil.
CTI BioPharma's Revenue for the trailing twelve months (TTM) ended in Mar. 2023 was $75.77 Mil. Therefore, CTI BioPharma's EV-to-Revenue for today is 15.69.
The historical rank and industry rank for CTI BioPharma's EV-to-Revenue or its related term are showing as below:
CTIC'
s EV-to-Revenue Range Over the Past 10 Years
Min: -2.05 Med: 8.35 Max: 237.67
Current: 15.69
During the past 13 years, the highest EV-to-Revenue of CTI BioPharma was 237.67. The lowest was -2.05. And the median was 8.35.
CTIC's EV-to-Revenue is not ranked
in the Biotechnology industry.
Industry Median: 8.37
vs CTIC: 15.69
As of today (2024-05-13), CTI BioPharma's stock price is $9.09.
CTI BioPharma's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2023 was $0.61. Therefore, CTI BioPharma's PS Ratio for today is 14.88.
CTI BioPharma EV-to-Revenue Historical Data
The historical data trend for CTI BioPharma's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of CTI BioPharma's EV-to-Revenue
For the Biotechnology subindustry, CTI BioPharma's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CTI BioPharma's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CTI BioPharma's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where CTI BioPharma's EV-to-Revenue falls into.
CTI BioPharma's current Enterprise Value is $1,188.68 Mil.
CTI BioPharma's Revenue for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $75.77 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CTI BioPharma's share price for today is $9.09.
CTI BioPharma's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.61.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CTI BioPharma EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of CTI BioPharma's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
CTI BioPharma (CTI BioPharma) Business Description
CTI BioPharma Corp is a biopharmaceutical company focused on the acquisition, development, and commercialization of less toxic and more effective cancer therapies. Its therapeutic area is blood-related cancers. Its products under the pipeline include Pacritinib. Pacritinib is an investigational oral kinase inhibitor for the treatment of adult patients with myelofibrosis.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CTIC has been successfully added to your 